An error occurred retrieving publication content to display, please try again.
Home >> Journals >> Health Technology Assessment >> Page Not FoundPlease choose a page from the navigation or try a website search above to find the information you need.
{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young & Allan Wailoo.
Matt Stevenson 1,*, Rachel Archer 1, Jon Tosh 1, Emma Simpson 1, Emma Everson-Hock 1, John Stevens 1, Monica Hernandez-Alava 1, Suzy Paisley 1, Kath Dickinson 1, David Scott 2, Adam Young 3, Allan Wailoo 1
1 School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2 Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK
3 Department of Rheumatology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK
* Corresponding author Email: m.d.stevenson@sheffield.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
[Image - Crossmark status check]The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Response by Professor Matt Stevenson on 2 June 2021 at 9:51 AM
Report updated in 2021 and new results presented in NIHR131265
This report was updated in 2021 and should be read in conjunction with NIHR131265, related award - https://fundingawards.nihr.ac.uk/award/NIHR131265 New results were presented to the NICE Appraisal Committee after multiple changes had been made to the modelling previously considered by NICE. These changes included: 1) using the latest prices, associated with some interventions noting that some had considerably fallen in price, 2) acknowledging that patients with moderate RA would receive biologic therapy when they progressed to severe, and 3) only allowing rituximab and tocilizumab treatment in patients with severe RA. A description of the work is presented as an Appendix to the initial HTA monograph. However, the cost-effectiveness results are commercial-in-confidence and cannot be reported in public.
An error has occurred in processing the XML document
© NIHR 2024